West Pharma (WST) Tops Q1 EPS by 22c, provides guidance

West Pharma (NYSE: WST) reported Q1 EPS of $1.45, $0.22 better than the analyst estimate of $1.23. Revenue for the quarter came in at $698 million versus the consensus estimate of $684.94 million.

GUIDANCE:

West Pharma sees FY2025 EPS of $6.15-$6.35, versus the consensus of $7.02. West Pharma sees FY2025 revenue of $2.945-2.975 billion, versus the consensus of $3.093 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Kalshi in early talks for IPO - The Information
• Happy Belly Food Group raises $8.35M through warrant exercises
• Grizzly Discoveries closes private placement raising $349,044